Abstract
We report the radiochemical synthesis of a specific MAO B inhibitor, namely 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[11C]-2(3H)-one (2b) (in vitro IC50=4nM and selectivity over 71000 for MAO B), by cyclization of its hydrazide precursor1 with [11C]phosgene. The reaction occurred within 2 min. The product obtained after HPLC purification,2b, had a high specific activity (11.1–22.2 GBq/µmol), allowing its use in experiments as a radiotracer in vivo. Biodistribution of2b in the CNS and in the peripheral organs of the rat, and positron emission tomography (PET) studies in the living baboon brain, pretreated or not withl-deprenyl (1 mg/kg, 1 h), an irreversible MAO B-specific inhibitor, were undertaken. The results showed a good uptake of2b in all organs of the rat, with a rapid clearance from the blood (10 min). Metabolite analyses in plasma and in the diencephalon of the rat showed that2b was the only radioactive compound in brain structure whereas in plasma three other radioactive products appeared. PET experiments show that in thel-deprenyl-pretreated baboon brain, specific binding of2b represents around 70% of total radioactivity, whereas in the blood and plasma the radioactivity cleared rapidly (15 min).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue.Biochem Pharmacol 1968; 17: 1285–1297.
Bach AWJ, Lan NC, Johnson DL, Abell CW, Bambenek ME, Kwan SW, Seeburg PH, Shih JC. cDNA cloning of human liver monoamine oxidase A and B: molecular bases of differences in enzymatic properties.Proc Natl Acad Sci USA 1988; 85: 4934–4938.
Hsu Y-PP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO. Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences.J Neurochem 1988; 51: 1321–1324.
Pintar JE, Barbosa J, Francke U, Castiglione CM, Hawkins M Jr, Breakefield XO. Gene for monoamine oxidase type A assigned to the human X chromosome.J Neurosci 1981; 1: 166–175.
The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease.N Engl J Med 1989; 321: 1364–1371.
Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.Science 1989; 245: 519–522.
Arnett CD, Fowler JS, MacGregor RR, Schlyer DJ, Wolf AP, Långström B, Halldin C. Turnovers of brain monoamine oxidase measured in vivo by positron emission tomography usingl-[11C]deprenyl.J Neurochem 1987; 49: 522–527.
Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer DJ, Christman D, Logan J, Smith M, Sachs H, Aquilonius SM, Bjurling P, Halldin C, Hartvig P, Leenders KL, Lundqvist H, Oreland L, Stålnacke C-G, Långström B. Mapping human brain monoamine oxidase A and B with11C-labelled suicide inactivators and PET.Science 1987; 235: 481–485.
Bench CJ, Price GW, Lammertsma AA, Luthra JC, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, Biziere K, McClelland GR, Jamienson VL, Wood ND, Frackowiak RSJ. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.Eur J Clin Pharmacol 1991; 40: 169–173.
Lammerstma AA, Bench CJ, Price GW, Cremer JE, Luthra SK, Turton D, Wood ND, Frackowiak RSJ. Measurement of cerebral monoamine oxidase B activity usingl-[11C]-deprenyl and dynamic positron emission tomography.J Cereb Blood Flow Metab 1991; 11: 545–556.
Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang G-J, Wolf AP, Pappas N, Axeloff D, Shea C, Gatley SJ, Dorflinger E, Yoo K, Morawsky L, Fazzini E. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19-6327.Neurology 1993; 43: 1984–1992.
Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schlyer DJ, Wolf AP, Pappas N, Alexoff D, Shea C, Dorflinger E, Kruchowy L, Yoo K, Fazzini E, Patlak C. Slow recovery of human brain MAO B afterl-deprenyl (selegeline) withdrawal.Synapse 1994; 18: 86–93.
Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, Långström B. Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]l-deprenyl in living baboon brain.J Neurochem 1988; 51: 1524–1534.
Plenevaux A, Dewey SL, Fowler JS, Guillaume M, Wolf AP. Synthesis of (R)-(−)- and (S)-(+)-4-fluorodeprenyl and (R)-(−)-and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.J Med Chem 1990; 33: 2015–2019.
Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R. 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monoamine oxidase type B inhibitors.J Med Chem 1993; 36: 1157–1167.
Synthélabo-Delalande, European Patent No. 0348257, 27.12.1989.
Mazouz F, Lebreton L, Milcent R, Burstein C. Inhibition of monoamine oxidase types A and by by 2-aryl-4H-1,3,4-oxadiazine-5(6H)-one derivatives.Eur J Med Chem 1988; 23: 441–451.
Mazous F, Lebreton L, Milcent R, Burstein C. 5-Aryl-1,3,4-oxadiazol-2(3H)-one derivatives and sulfur analogoues as new selective and competitive monoamine oxidase type B inhibitors.Eur J Med Chem 1990; 25: 659–671.
Landais P, Crouzel C. A new synthesis of carbon-11 labelled phosgene.Appl Radiat Isot 1987; 38: 297–300.
Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to high performance liquid chromatographic analysis.J Chromatogr 1981; 226: 455–460.
Riche D, Hantraye P, Guibert B, Naquet R, Loch C, Maziére B, Maziére M. Anatomical atlas of the baboon's brain in the orbitomeatal plane used in experimental positron emission tomography.Brain Res Bull 1988; 20: 283.
Saura J, Kettler R, Da Prada M, Richards JG. Quantitative enzyme radioautography with3H-Ro 41-1049 and3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain.J Neurosci 1992; 12: 1977–1999.
Willoughby J, Glover V, Sandler M. Histochemical localisation of monoamine oxidase A and B in rat brain.J Neural Transm 1988; 74: 29–42.
Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons.Proc Natl Acad Sci USA 1982; 79: 6385–6389.
Kalaria RN, Harik SI. Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human.J Neurochem 1987; 49: 856–864.
Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain.Science 1985; 230: 181–183
Delforge J, Janier M, Syrota A, Crouzel C, Vallois J-M, Cayla J, Lancon J-P, Mazoyer BM. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart.Circulation 1990; 82: 1494–1504.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernard, S., Fuseau, C., Schmid, L. et al. Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[11C]-2(3H)-one. Eur J Nucl Med 23, 150–156 (1996). https://doi.org/10.1007/BF01731838
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01731838